Evonik Buys Alkion Biopharma

Germany’s Evonik is strengthening its portfolio of specialty active...
Germany’s Evonik is strengthening its portfolio of specialty active ingredients with an agreement to purchase French start-up company Alkion Biopharma for an undisclosed sum. (Lichtmeister/Shutterstock)

Germany’s Evonik is strengthening its portfolio of specialty active ingredients with an agreement to purchase French start-up company Alkion Biopharma for an undisclosed sum. Headquartered in Evry, Alkion specializes in developing biotechnological active ingredients for the cosmetics industry. The company has developed methods to cultivate plant biomass under laboratory conditions and can obtain extracts with an exceptionally high yield of complex ingredients.

The entire process takes place without altering the plant genome and results, said Franck Michoux, Alkion’s founder and CEO, in unique, innovative cosmetic actives. With this acquisition, Evonik can now offer customers highly effective customized plant-based ingredients and product concepts that set themselves apart from competitors, said Tammo Boinowitz, head of Evonik’s personal care business.

The transaction is due to be completed this month. Alkion was originally founded as a spin-off from Imperial College London in 2011.

Virtual Event

Downstream Purification
Bioprocess Forum

Downstream Purification

Save the Date: November 21+25, 2025
Join leading scientists, process engineers, and biomanufacturing innovators for a two-day virtual event exploring the latest breakthroughs in downstream purification.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.